Immunic, Inc. (IMUX): Price and Financial Metrics


Immunic, Inc. (IMUX): $6.11

0.03 (+0.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMUX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMUX Stock Price Chart Interactive Chart >

Price chart for IMUX

IMUX Price/Volume Stats

Current price $6.11 52-week high $15.12
Prev. close $6.08 52-week low $4.96
Day low $5.97 Volume 156,000
Day high $6.35 Avg. volume 289,253
50-day MA $8.57 Dividend yield N/A
200-day MA $9.65 Market Cap 186.60M

Immunic, Inc. (IMUX) Company Bio


Immunic Inc. (formerly Vital Therapies) is a biotherapeutic company developing a cell-based therapy targeting the treatment of liver failure. The company was founded in 2003 and is based in San Diego, California.


IMUX Latest News Stream


Event/Time News Detail
Loading, please wait...

IMUX Latest Social Stream


Loading social stream, please wait...

View Full IMUX Social Stream

Latest IMUX News From Around the Web

Below are the latest news stories about Immunic Inc that investors may wish to consider to help them evaluate IMUX as an investment opportunity.

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent activity.

Yahoo | February 24, 2022

Immunic FY 2021 Earnings Preview

Immunic (NASDAQ:IMUX) is scheduled to announce FY earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$3.73...

Seeking Alpha | February 23, 2022

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that Evelyn Peelen, Ph.D., Senior Manager Translational Pharmacology at Immunic, will present preclinical data on the potent anti-inflammatory activity of vidofludimus calcium (IMU-838), the company's selective oral DHODH inhibitor, at the 17th Congress of European Crohn's and Colitis

Yahoo | February 18, 2022

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2021, including a corporate update, on Thursday, February 24, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

Yahoo | February 17, 2022

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | February 8, 2022

Read More 'IMUX' Stories Here

IMUX Price Returns

1-mo -16.19%
3-mo -42.84%
6-mo -26.56%
1-year -54.77%
3-year -34.86%
5-year -94.64%
YTD -36.15%
2021 -37.41%
2020 57.63%
2019 27.63%
2018 -96.81%
2017 36.78%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.879 seconds.